Home > Insider Trading > Filing (0000885590-15-000078)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
885590	Valeant Pharmaceuticals International Inc.	VRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1426004	Michael J. Pearson	2150 St. Elzear Blvd. West Laval A8 H7L 4A8	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, No Par Value	Disposition	2015-11-05	147,054	$74.67	2,665,009	No	4	S	Direct
Common Stock, No Par Value	Disposition	2015-11-05	800,345	$76.66	1,864,664	No	4	S	Direct
Common Stock, No Par Value	Disposition	2015-11-05	350,000	$84.26	1,514,664	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, No Par Value	175,000	Indirect	In Trust by Spouse

Footnotes

These shares were held by Goldman Sachs as collateral to secure Mr. Pearson's obligations under personal loans Mr. Pearson obtained from Goldman Sachs, to, among other things, finance charitable contributions, including a contribution to Duke University, helping to fund a community swimming pool, purchase shares of the issuer, and meet certain tax obligations related to the vesting and payment of compensatory equity awards. On November 5, 2015, Goldman Sachs ordered the sale of these shares in repayment of the loans. After repayment of the loans with the proceeds from the sale by Goldman Sachs, the loan agreements will terminate and there will be no amounts outstanding under those agreements.
The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $74.64 to $74.95. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $76.34 to $77.25. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.